末梢動脈疾患（PAD）- 世界市場の考察、競合情勢、市場予測（2030年）

世界の末梢動脈疾患（PAD）の市場規模は、2023年に37億5,764万米ドル、2030年までに54億6,902万米ドルに達し、2024年～2030年の予測期間にCAGRで6.64％の成長が見込まれます。市場は、老年人口の負担の増加、世界中での末梢動脈疾患（PAD）と動脈硬化の有病率の上昇などの要因により、大幅な市場成長を示しています。さらに、肥満、糖尿病、高血圧の有病率の上昇、製品の発売と承認の増加などが、市場における末梢動脈疾患（PAD）の必要性を生み出します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRでの成長が見込まれます。

末梢動脈疾患（PAD）の市場力学

末梢動脈疾患（PAD）市場の成長に影響を与える主な要因の1つは、世界中で末梢動脈疾患（PAD）の有病率が増加していることです。

例えば、Global Burden of Disease（2019）によると、2019年、全世界で40～70歳のPAD有病者数は5,640万人でした。米国疾病予防管理センター（CDC）（2022）によると、米国では2022年に40歳以上の約650万人がPADに罹患していると推定されています。

さらに、PADは主に動脈硬化と呼ばれる動脈内の脂肪性プラークの蓄積によって引き起こされるため、動脈硬化の有病率の増加が結果としてPADの症例を増加させ、市場におけるPADの治療機器および治療薬の需要をさらに増加させる可能性があります。例えば、Heart Research Instituteが実施した最新の研究では、40歳を超えると、全体的に健康な人が深刻な動脈硬化を発症する可能性は約50％で、このリスクは年齢とともに増加すると結論付けています。60歳を超えるとほとんどの人が何らかの動脈硬化を持っていますが、多くの場合、目立った症状はありません。

したがって、さまざまな末梢動脈疾患（PAD）や動脈硬化の有病率の増加は、末梢動脈疾患（PAD）向けの機器や治療薬の需要を増加させ、それによって市場全体の成長を促進します。

さらに、PADやその危険因子にかかりやすい老人の負担が世界中で増加していることは、調査期間（2022年～2028年）に末梢動脈疾患（PAD）市場を後押しする見込みです。世界保健機関（WHO）（2022）によると、2020年に全世界で60歳以上の高齢者数が5歳未満の小児数を上回っています。上記の資料によると、2030年までに世界の6人に1人が60歳以上の高齢者になると推定されています。この時、60歳以上の人口に占める割合は、2020年の10億人から2030年までに14億人に増加します。さらに2050年までに、世界の60歳以上の人口は倍増し、21億人近くになります。また、80歳以上の高齢者の数も同じ資料から提供されており、2020年～2050年に3倍となり、世界で4億2,600万人に達すると予測されています。老年人口の増加は、老年人口は末梢動脈疾患（PAD）に罹患しやすいことから、末梢動脈疾患（PAD）の治療薬や治療機器に対する需要を増加させ、末梢動脈疾患（PAD）市場全体の成長を増大させます。

さらに、肥満、糖尿病、高血圧の有病率の増加は、末梢動脈疾患（PAD）のリスクを増加させ、それによって治療機器や治療薬の需要を増加させます。

したがって、2024年～2030年の予測期間に、上記の要因が総合的に末梢動脈疾患（PAD）市場全体を牽引します。

しかし、さまざまな機器の高いコストや、さまざまな治療に関連する有害事象などが、末梢動脈疾患（PAD）市場の成長にとっての課題となる可能性があります。

末梢動脈疾患（PAD）市場は、COVID-19パンデミック期間にマイナスの影響を受けました。パンデミックの発生は、がん、糖尿病、心血管疾患、脳卒中などの慢性疾患に対する外来受診のキャンセルや、緊急性のない病院や処置の中止につながりました。その結果、上記の疾患の定期的な治療を受ける患者数が減少しました。さらに、COVID-19患者の治療が優先されたため、多くの選択的手術が延期されました。さらに、サプライチェーンや原材料などの制約により、機器や薬剤の製造がストップし、市場での治療機器や治療薬の不足につながっています。しかし、COVID-19のワクチン開発が景気回復のきっかけとなりました。また、ロックダウン規制の緩和や経済状況の正常化により、前述の疾患の治療に向けた外来受診や手術などの通常の医療サービスが再開されるようになり、末梢動脈疾患（PAD）市場における製品需要が軌道に乗りました。

当レポートでは、世界の末梢動脈疾患（PAD）市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 末梢動脈疾患（PAD）市場レポートのイントロダクション

第2章 末梢動脈疾患（PAD）市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 末梢動脈疾患（PAD）市場の主な要因の分析

• 末梢動脈疾患（PAD）市場の促進要因
• 末梢動脈疾患（PAD）市場の抑制要因と課題
• 末梢動脈疾患（PAD）市場の機会

第5章 末梢動脈疾患（PAD）市場のポーターのファイブフォース分析

第6章 末梢動脈疾患（PAD）市場に対するCOVID-19の影響分析

第7章 末梢動脈疾患（PAD）市場のレイアウト

• 治療タイプ別
  • 機器
  • 薬剤
• エンドユーザー別
  • 病院
  • 外来手術センター
  • 専門クリニック
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 末梢動脈疾患（PAD）市場の企業と製品のプロファイル

• Medtronic
• Otivio
• Koninklijke Philips N.V.
• B. Braun SE
• Boston Scientific Corporation
• BD
• Terumo Corporation
• Biotronik
• Cordis
• Abbott
• AngioDynamics
• Cardiovascular Systems, Inc.
• Bluesail Medical Co., Ltd.
• Contego Medical, Inc.
• Argon Medical
• REX MEDICAL
• Merck & Co., Inc.
• Sanofi
• Johnson and Johnson Services, Inc.
• Reflow Medical Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Peripheral Artery Disease (PAD) Market
• Table 3: Peripheral Artery Disease (PAD) Market Analysis in Global (2021-2030)
• Table 4: Peripheral Artery Disease (PAD) Market Analysis in Global by Treatment Type (2021-2030)
• Table 5: Peripheral Artery Disease (PAD) Market Analysis in Global by End-user (2021-2030)
• Table 6: Peripheral Artery Disease (PAD) Market Analysis in Global by Geography (2021-2030)
• Table 7: Peripheral Artery Disease (PAD) Market Analysis in North America (2021-2030)
• Table 8: Peripheral Artery Disease (PAD) Market Analysis in North America by Country (2021-2030)
• Table 9: Peripheral Artery Disease (PAD) Market Analysis in the US (2021-2030)
• Table 10: Peripheral Artery Disease (PAD) Market Analysis in Canada (2021-2030)
• Table 11: Peripheral Artery Disease (PAD) Market Analysis in Mexico (2021-2030)
• Table 12: Peripheral Artery Disease (PAD) Market Analysis in Europe (2021-2030)
• Table 13: Peripheral Artery Disease (PAD) Market Analysis in Europe by Country (2021-2030)
• Table 14: Peripheral Artery Disease (PAD) Market Analysis in France (2021-2030)
• Table 15: Peripheral Artery Disease (PAD) Market Analysis in Germany (2021-2030)
• Table 16: Peripheral Artery Disease (PAD) Market Analysis in the UK (2021-2030)
• Table 17: Peripheral Artery Disease (PAD) Market Analysis in Italy (2021-2030)
• Table 18: Peripheral Artery Disease (PAD) Market Analysis in Spain (2021-2030)
• Table 19: Peripheral Artery Disease (PAD) Market Analysis in the Rest of Europe (2021-2030)
• Table 20: Peripheral Artery Disease (PAD) Market Analysis in Asia-Pacific (2021-2030)
• Table 21: Peripheral Artery Disease (PAD) Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 22: Peripheral Artery Disease (PAD) Market Analysis in China (2021-2030)
• Table 23: Peripheral Artery Disease (PAD) Market Analysis in Japan (2021-2030)
• Table 24: Peripheral Artery Disease (PAD) Market Analysis in India (2021-2030)
• Table 25: Peripheral Artery Disease (PAD) Market Analysis in Australia (2021-2030)
• Table 26: Peripheral Artery Disease (PAD) Market Analysis in South Korea (2021-2030)
• Table 27: Peripheral Artery Disease (PAD) Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 28: Peripheral Artery Disease (PAD) Market Analysis in the Rest of the World (2021-2030)
• Table 29: Peripheral Artery Disease (PAD) Market Analysis in the Rest of the World by Region (2021-2030)
• Table 30: Peripheral Artery Disease (PAD) Market Analysis in the Middle East (2021-2030)
• Table 31: Peripheral Artery Disease (PAD) Market Analysis in Africa (2021-2030)
• Table 32: Peripheral Artery Disease (PAD) Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Peripheral Artery Disease (PAD) Market
• Figure 3: Peripheral Artery Disease (PAD) Market Analysis in Global (2021-2030)
• Figure 4: Peripheral Artery Disease (PAD) Market Analysis in Global by Treatment Type (2021-2030)
• Figure 5: Peripheral Artery Disease (PAD) Market Analysis in Global by End-user (2021-2030)
• Figure 6: Peripheral Artery Disease (PAD) Market Analysis in Global by Geography (2021-2030)
• Figure 7: Peripheral Artery Disease (PAD) Market Analysis in North America (2021-2030)
• Figure 8: Peripheral Artery Disease (PAD) Market Analysis in North America by Country (2021-2030)
• Figure 9: Peripheral Artery Disease (PAD) Market Analysis in the US (2021-2030)
• Figure 10: Peripheral Artery Disease (PAD) Market Analysis in Canada (2021-2030)
• Figure 11: Peripheral Artery Disease (PAD) Market Analysis in Mexico (2021-2030)
• Figure 12: Peripheral Artery Disease (PAD) Market Analysis in Europe (2021-2030)
• Figure 13: Peripheral Artery Disease (PAD) Market Analysis in Europe by Country (2021-2030)
• Figure 14: Peripheral Artery Disease (PAD) Market Analysis in France (2021-2030)
• Figure 15: Peripheral Artery Disease (PAD) Market Analysis in Germany (2021-2030)
• Figure 16: Peripheral Artery Disease (PAD) Market Analysis in the UK (2021-2030)
• Figure 17: Peripheral Artery Disease (PAD) Market Analysis in Italy (2021-2030)
• Figure 18: Peripheral Artery Disease (PAD) Market Analysis in Spain (2021-2030)
• Figure 19: Peripheral Artery Disease (PAD) Market Analysis in the Rest of Europe (2021-2030)
• Figure 20: Peripheral Artery Disease (PAD) Market Analysis in Asia-Pacific (2021-2030)
• Figure 21: Peripheral Artery Disease (PAD) Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 22: Peripheral Artery Disease (PAD) Market Analysis in China (2021-2030)
• Figure 23: Peripheral Artery Disease (PAD) Market Analysis in Japan (2021-2030)
• Figure 24: Peripheral Artery Disease (PAD) Market Analysis in India (2021-2030)
• Figure 25: Peripheral Artery Disease (PAD) Market Analysis in Australia (2021-2030)
• Figure 26: Peripheral Artery Disease (PAD) Market Analysis in South Korea (2021-2030)
• Figure 27: Peripheral Artery Disease (PAD) Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 28: Peripheral Artery Disease (PAD) Market Analysis in the Rest of the World (2021-2030)
• Figure 29: Peripheral Artery Disease (PAD) Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 30: Peripheral Artery Disease (PAD) Market Analysis in the Middle East (2021-2030)
• Figure 31: Peripheral Artery Disease (PAD) Market Analysis in Africa (2021-2030)
• Figure 32: Peripheral Artery Disease (PAD) Market Analysis in South America (2021-2030)
• Figure 33: Market Drivers
• Figure 34: Market Barriers
• Figure 35: Market Opportunities
• Figure 36: PORTER's Five Force Analysis

Peripheral Artery Disease (PAD) Market By Treatment Type (Devices [Angioplasty Balloon, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, And Peripheral Guidewires], And Drugs), By End-User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of peripheral artery diseases, and arteriosclerosis, and the rising geriatric population burden prone to pad and other risk factors across the globe

The global peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030. The peripheral artery disease (PAD) market is observing remarkable market growth due to the factors such as the escalating burden of the geriatric population and the rising prevalence of peripheral artery disease (PAD) and arteriosclerosis across the globe. Further, the rising prevalence of obesity, diabetes, and high blood pressure, increasing product launches and approvals, and others will create a necessity for peripheral artery disease (PAD) in the market. Therefore, the market for peripheral artery disease (PAD) is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Peripheral Artery Disease (PAD) Market Dynamics:

One of the key factors influencing the growth of peripheral artery disease in the market is the increasing prevalence of peripheral artery diseases (PAD) across the world.

For instance, as per Global Burden of Disease 2019, in 2019, there were 56.4 million prevalent cases of PAD among those aged 40-70, worldwide. According to the Centers for Disease Control and Prevention (CDC) 2022, it was estimated that approximately 6.5 million people aged 40 and older in the United States had PAD, in 2022.

Further, PAD is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis, thereby increasing the prevalence of arteriosclerosis can ultimately increase the cases of PAD and further increase the demand for PAD treatment devices and drugs in the market. For instance, the latest study conducted by Heart Research Institute concluded that over the age of 40, people in general good health have about a 50% chance of developing serious atherosclerosis, with this risk increasing with age. Most people over the age of 60 have some atherosclerosis, but often do not have noticeable symptoms.

Thus, the increasing prevalence of various peripheral artery diseases and arteriosclerosis will increase the demand for peripheral artery disease devices and drugs, thereby propelling the overall market growth.

Further, the increasing geriatric burden prone to PAD and its risk factors across the globe will aid in propelling the market of peripheral artery disease (PAD) during the study period (2022 - 2028). As per World Health Organization (WHO) 2022, in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years, across the globe. The data provided by the above-mentioned source estimated that by 2030, one in six people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion, in 2030, worldwide. Moreover, by 2050, the world's population of people aged 60 years and older will double which is nearly 2.1 billion. The number of persons aged 80 years or older was also provided by the same source, which is expected to triple between 2020 and 2050 to reach 426 million, globally. The increasing elderly population will increase the demand for peripheral artery disease (PAD) drugs and treatment devices as they are more prone to peripheral artery diseases, thereby increasing the overall market growth of peripheral artery disease (PAD).

Additionally, the increasing rising prevalence of obesity, diabetes, and high blood pressure will increase the risk of peripheral artery disease, thereby increasing the demand for its treatment devices and drugs.

Therefore, the factors stated above collectively will drive the overall peripheral artery disease (PAD) market during the forecast period from 2024-2030.

However, the high cost of different devices, adverse events related to various treatments, and others may prove to be challenging factors for peripheral artery disease (PAD) market growth.

The peripheral artery disease (PAD) market was negatively impacted during the period of COVID- 19 pandemic. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitals and procedures for chronic disorders such as cancers, diabetes, cardiovascular disorders, stroke, and others. This resulted in a reduced number of patients with routine treatments of the above-mentioned disorders. Moreover, many elective surgeries were postponed as treatment of patients suffering from coronavirus infection was on priority. Additionally, the restrictions on the supply chain, raw materials, and other resources halted the manufacturing of devices and drugs, leading to a shortage of treatment devices and drugs in the market. However, the vaccine development of COVID-19 initiated the process of economic recovery. Also, the easing of lockdown restrictions and the return of normalcy in the economic landscape initiated the process of resumption of regular healthcare services such as outpatients visits and surgeries for the treatment of aforementioned ailments, thereby bringing the demand for products on track in the peripheral artery disease (PAD) market.

Peripheral Artery Disease (PAD) Market Segment Analysis:

Peripheral Artery Disease (PAD) Market by Treatment Type (Devices [Angioplasty Balloon, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and, Peripheral Guidewires], and Drugs), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the treatment type segment of the peripheral artery disease (PAD) market, the angioplasty balloon segment is expected to have a revenue share of 43.83% in the year 2023. This was primarily owing to the rising focus of manufacturers towards developing technologically advanced angioplasty balloons for improved and efficient removal of clots and plaques and the various advantages offered by the category.

Moreover, the angioplasty balloon is a minimally invasive vascular procedure to open narrowed or blocked arteries in patients with peripheral arterial disease.

The angioplasty balloon can also relieve intermittent claudication in lesser time, which is a symptom of peripheral arterial disease.

Additionally, it is the most effective method for the widening of larger arteries, arteries with short blocked areas, or arteries that are narrowed and not blocked.

Further, the increasing product launches and regulatory approvals of an angioplasty balloon will aid in increasing its demand in the market. For instance, in June 2020, the US Food and Drug Administration (FDA) cleared INFINITY Angioplasty Balloon's new balloon platform INFINITY Angioplasty Balloon Catheter for percutaneous transluminal angioplasty (PTA) treatment of peripheral arterial disease (PAD).

Therefore, owing to the aforementioned factors, the category angioplasty balloon is expected to witness considerable growth eventually contributing to the overall growth of the global peripheral artery disease (PAD) market during the forecast period.

North America is expected to dominate the overall Peripheral Artery Disease (PAD) Market:

Among all the regions, North America is expected to hold the largest share of 43.53% in the peripheral artery disease (PAD) market in 2022 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the growing government initiatives to raise awareness regarding the effective treatment of peripheral artery diseases, expanding burden of elderly patients prone to various cardiovascular disorders, the increasing prevalence of obesity, hypertension, and diabetes, increasing product launches, and the presence of advanced healthcare facilities in the region, which will boost the peripheral artery disease market in North America during the forecast period.

For instance, as per the US Census Bureau 2022 report, more than 54 million adults ages 65 and older living in the United States, in 2022. Further by 2050, the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million roughly 20% of the overall U.S. population. The elderly population especially people above 50 years are more prone to peripheral artery disease.

The increasing prevalence of obesity and overweight will increase the market of peripheral artery disease as obese patients are 3-5 times more likely to develop the most severe complication of PAD. As per the data reported by the Centers for Disease Control and Prevention (CDC) 2019, all US states and territories have an obesity rate of at least 20%, in 2019. The source also stated that nearly one out of every three United States adults is obese.

Moreover, the increasing product launches, approvals, and other regulatory activities among the key players in the region will aid in increasing the demand for peripheral artery disease treatment devices and drugs. For instance, in September 2019, Concept Medical received the FDA Breakthrough Therapy designation for its sirolimus-coated balloon catheter developed for treating peripheral artery disease below the knee.

Also, in May 2022, Medtronic announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the peripheral artery disease (PAD) market.

Peripheral Artery Disease (PAD) Market Key Players:

Some of the key market players operating in the Peripheral Artery Disease (PAD) market include Medtronic, Otivio, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Cook, Bayer AG, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX MEDICAL, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Reflow Medical Inc., and others.

Recent Developmental Activities in the Peripheral Artery Disease (PAD) Market:

In June 2020, the US Food and Drug Administration (FDA) cleared INFINITY Angioplasty Balloon's new balloon platform INFINITY Angioplasty Balloon Catheter for percutaneous transluminal angioplasty (PTA) treatment of peripheral arterial disease (PAD).

In September 2020, Abbott Laboratories started the LIFE-BTK clinical trial to assess the effectiveness and safety of its Esprit BTK Everolimus-Eluting Resorbable Scaffold System. This is the Investigational Device Exemption (IDE) trial in the U.S. that is expected to help people battling the advanced stages of peripheral artery disease (PAD).

In June 2020, Becton, Dickinson and Company acquired, Straub Medical AG, a private corporation. Medical atherectomy and thrombectomy devices are developed by Straub Medical AG for the treatment of venous and peripheral arterial disorders (PAD).

Key Takeaways From the Peripheral Artery Disease (PAD) Market Report Study

Market size analysis for current peripheral artery disease (PAD) market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the peripheral artery disease (PAD) market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global peripheral artery disease (PAD) market.

Various opportunities available for the other competitor in the peripheral artery disease (PAD) market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current peripheral artery disease (PAD) market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for peripheral artery disease (PAD) market growth in the coming future?

Target Audience who can be benefited from this Peripheral Artery Disease (PAD) Market Report Study

Peripheral artery disease (PAD) products providers

Research organizations and consulting companies

Peripheral artery disease (PAD) -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in peripheral artery disease (PAD)

Various end users who want to know more about the peripheral artery disease (PAD) market and the latest technological developments in the peripheral artery disease (PAD) market.

Frequently Asked Questions for the Peripheral Artery Disease (PAD) Market:

1. What is peripheral artery disease (PAD)?

Peripheral artery disease (PAD) is a common cardiovascular condition that is caused by plaque build-up in the arteries, resulting in restricted blood flow to the limbs. Peripheral artery disease is also linked to diabetes, aging, and high blood pressure.

2. What is the global market for peripheral artery disease (PAD)?

The global peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030.

3. What are the drivers for the global peripheral artery disease (PAD) market?

The peripheral artery disease (PAD) market is witnessing positive market growth owing to the factors such as the rising prevalence of peripheral artery disease (PAD) and arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, rising demand of minimally-invasive procedures, increasing product launches and approvals, presence of key players in the market, and others will create an exigency for the peripheral artery disease (PAD) market.

4. Who are the key players operating in the global peripheral artery disease (PAD) market?

Some of the key market players operating in the peripheral artery disease (PAD) market include Medtronic, Otivio, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Cook, Bayer AG, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX MEDICAL, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Reflow Medical Inc., and others.

5. Which region has the highest share in the peripheral artery disease (PAD) market?

Among all the regions, North America is estimated to amass a significant revenue share in the global peripheral artery disease (PAD) market. This can be ascribed to the growing government initiatives to raise awareness regarding the effective treatment of peripheral artery diseases, the rising burden of elderly patients, the increasing prevalence of obesity, hypertension, and diabetes, the presence of advanced healthcare facilities in the region, and others act as a supportive factor for the North America peripheral artery disease (PAD) market growth.

Table of Contents

1.Peripheral Artery Disease (PAD) Market Report Introduction

2. Peripheral Artery Disease (PAD) Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Peripheral Artery Disease (PAD) Market Key Factors Analysis

• 4.1. Peripheral Artery Disease (PAD) Market Drivers
  • 4.1.1. Rising prevalence of peripheral artery disease (PAD) and arteriosclerosis
  • 4.1.2. Rising prevalence of obesity, diabetes, and high blood pressure
  • 4.1.3. The growing burden of the elderly population
  • 4.1.4. Rising demand for minimally-invasive procedures
• 4.2. Peripheral Artery Disease (PAD) Market Restraints and Challenges
  • 4.2.1. High cost of different devices
  • 4.2.2. Adverse events related to various treatments
• 4.3. Peripheral Artery Disease (PAD) Market Opportunities
  • 4.3.1. Growing knowledge about the benefits of PAD devices in the market
  • 4.3.2. Growth opportunities in the emerging nation

5. Peripheral Artery Disease (PAD) Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Peripheral Artery Disease (PAD) Market

7. Peripheral Artery Disease (PAD) Market Layout

• 7.1. By Treatment Type
  • 7.1.1. Devices
    • 7.1.1.1. Angioplasty Balloon
    • 7.1.1.2. Angioplasty Stents
    • 7.1.1.3. Plaque Modification Devices
    • 7.1.1.4. Hemodynamic Flow Alteration Devices
    • 7.1.1.5. Peripheral Guidewires
  • 7.1.2. Drugs
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Ambulatory Surgical Centers
  • 7.2.3. Specialty Clinics
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.1.2. Canada Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.1.3. Mexico Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.2.2. Germany Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.2.4. Italy Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.2.5. Spain Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.3.2. Japan Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.3.3. India Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.3.4. Australia Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.3.5. South Korea Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia Pacific Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.4.2. Africa Peripheral Artery Disease (PAD) Market in USD million (2021-2030)
    • 7.3.4.3. South America Peripheral Artery Disease (PAD) Market in USD million (2021-2030)

8. Peripheral Artery Disease (PAD) Market Company and Product Profiles

• 8.1. Medtronic
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Otivio
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Koninklijke Philips N.V.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. B. Braun SE
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Boston Scientific Corporation
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. BD
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Terumo Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Biotronik
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Cordis
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Abbott
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. AngioDynamics
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Cardiovascular Systems, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Bluesail Medical Co., Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Contego Medical, Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Argon Medical
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. REX MEDICAL
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Merck & Co., Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Sanofi
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Johnson and Johnson Services, Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Reflow Medical Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us